Space Capsule With Cannabis Seeds, Ashes Of 166 People Crashes Into The Ocean
In a tragic turn of events, German aerospace startup The Exploration Company (TEC) has announced the failure of its ambitious Mission Possible. Launched on June 23, the mission aimed to return safely after orbiting the Earth twice with the ashes of 166 people and some hemp seeds. However, the capsule, named Nyx, sank into the Pacific Ocean upon its return to Earth.
The mission was designed by Texas-based space burial company Celestis, who envisioned not just sending the ashes into space but bringing them back to Earth as a symbolic gesture. After launch, the capsule successfully reached Earth's orbit and completed two orbits, with all onboard instruments functioning properly. However, contact was lost just minutes before its scheduled re-entry into Earth's atmosphere. It was expected to land safely in the Pacific Ocean, but TEC later confirmed that the capsule had crashed directly into the ocean. No parts or ashes could be recovered.
In addition to the human ashes, the capsule contained marijuana seeds as part of the Martian Grow Project, a citizen science mission to explore the feasibility of growing marijuana on Mars. Unfortunately, these seeds are now buried deep in the ocean.
Celestis co-founder Charles M. Chafer expressed deep sorrow over the incident, acknowledging the grief of the families involved in the mission. He praised their courage and highlighted the historical significance of their participation. Despite the mission's failure, he said the fact that the ashes of 166 people orbited the Earth remains a respectable achievement.
TEC has also recognised the technical shortcomings of the mission but emphasised the valuable lessons learned. The company has committed to launching similar missions in the future, aiming to achieve safe 'return space burials' and chart a new direction in the coming times.
Get breaking news, in-depth analysis, and expert perspectives on everything from geopolitics to diplomacy and global trends. Stay informed with the latest world news only on News18. Download the News18 App to stay updated!
First Published:
July 07, 2025, 12:10 IST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
5 hours ago
- Hindustan Times
Astronauts from India, Poland, Hungary depart space station for return flight
* Astronauts from India, Poland, Hungary depart space station for return flight Splashdown planned for Tuesday morning in Pacific off California * Undocking ends 18-day science outing aboard orbital laboratory * Mission marks US astronaut Peggy Whitson's 5th flight to space By Steve Gorman LOS ANGELES, - NASA retiree turned private astronaut Peggy Whitson and four crewmates from India, Poland and Hungary departed the International Space Station early on Monday and embarked on their return flight to Earth. A Crew Dragon capsule carrying the quartet undocked from the orbital laboratory at 7:15 a.m. EDT , ending the latest ISS visit organized by Texas-based startup Axiom Space in partnership with Elon Musk's California-headquartered rocket venture SpaceX. The Axiom astronauts, garbed in their helmeted white-and-black flightsuits, were seen in live video footage strapped into the crew cabin shortly before the vehicle separated from the station, orbiting some 260 miles over the east coast of India. A couple of brief rocket thrusts then pushed the capsule safely clear of the ISS. Whitson, 65, and her three Axiom crewmates - Shubhanshu Shukla, 39, of India, Sławosz Uznański-Wiśniewski, 41, of Poland, and Tibor Kapu, 33, of Hungary - spent 18 days aboard the space station conducting dozens of research experiments in microgravity. The mission stands as the fourth such flight since 2022 arranged by Axiom as the Houston-headquartered company builds on its business of putting astronauts sponsored by private companies and foreign governments into low-Earth orbit. For India, Poland and Hungary, the launch marked the first human spaceflight in more than 40 years and the first mission ever to send astronauts from their government's respective space programs to the ISS. If all goes as planned, the Dragon capsule will re-enter Earth's atmosphere at the end of a 22-hour return flight and parachute into the Pacific Ocean off the coast of California on Tuesday around 5:30 a.m. EDT . Dubbed "Grace" by its crew, the newly commissioned capsule flown for Axiom-4 was launched from NASA's Kennedy Space Center in Cape Canaveral in Florida on June 25, making its debut as the fifth vehicle in SpaceX's Crew Dragon fleet. Axiom-4 also marks the 18th crewed spaceflight logged by SpaceX since 2020, when Musk's rocket company ushered in a new NASA era by providing American astronauts their first rides to space from U.S. soil since the end of the space shuttle program nine years earlier. The Ax-4 multinational team was led by Whitson, who retired from NASA in 2018 after a pioneering career that included becoming the U.S. space agency's first female chief astronaut and the first woman to command an ISS expedition. Now director of human spaceflight for Axiom, she had logged 675 days in space, a U.S. record, during three previous NASA missions and a fourth flight to space as commander of the Axiom-2 crew in 2023. Her latest mission commanding Axiom-4 will extend her record by about three more weeks. Axiom, a 9-year-old venture co-founded by NASA's former ISS program manager, is one of a handful of companies developing a commercial space station of its own intended to eventually replace the ISS, which NASA expects to retire around 2030. This article was generated from an automated news agency feed without modifications to text.
Hindustan Times
10 hours ago
- Hindustan Times
From no alcohol to vegetarian food, inside Shubhanshu Shukla's ISS farewell
Close your eyes and picture a farewell party. We're sure you're thinking of music, food and a few teary-eyed hugs. But when the goodbye happens hundreds of kilometers above Earth, the situation looks a little different. Aboard the International Space Station, Indian astronaut Shubhanshu Shukla recently received a send-off that was minimal. No clinking glasses, no lavish spread – just floating food pouches, warm camaraderie and a sense of shared achievement, reports News18. Also, in keeping with ISRO tradition, there was no non-vegetarian fare. Shubhanshu Shukla, 39, is a Group Captain and test pilot in the Indian Air Force (HT_PRINT) Also read: Astronaut Shubhanshu Shukla's family: He showed us sunrise from ISS; waiting for him to return tomorrow What's allowed at an ISS farewell? Shukla and a few fellow astronauts were given a low-key but meaningful farewell aboard the ISS, streamed live to Earth, sparking plenty of curiosity online. Is there cake? Can they play music? and much more. While images of astronauts doing rounds online in T-shirts might suggest a relaxed vibe, space life is definitely not casual. In fact, any crew gathering, including farewells, must be coordinated with Earth-based mission control centers in Houston and Moscow. Reportedly, every ceremony and every moment follows strict protocol. Farewells, too, are defined by the 1998 Intergovernmental Agreement and the Crew Code of Conduct (CCOC), signed by space agencies like NASA, Roscosmos, ESA, JAXA and CSA. Even in microgravity, rules guide everything, from who speaks when to what foods are permitted, and no confetti. Also read: India's Shubhanshu Shukla, Axiom-4 crew begin journey back to Earth: When, where they'll land Food items that are allowed Forget the champagne toasts or juicy steaks – those don't fly in space. On the ISS, NASA strictly prohibits alcohol, non-veg meals, or anything intoxicating. Food is limited to vacuum-sealed, pre-approved packets like rehydrated mac and cheese or the occasional chocolate bar. Even utensils need prior clearance. Why so strict? In a closed-loop system where air is recycled, even a strong food smell can throw things off. In space, even celebrations have to follow rules. Muted music, emotional goodbyes Music is allowed aboard the ISS, but only if it doesn't disturb communication or scientific work. Instead, astronauts connect with family through scheduled video calls. FAQs: 1. Who is Shubhanshu Shukla? He (39) is a Group Captain and test pilot in the Indian Air Force and a Gaganyatri with ISRO. 2. What is his current mission? As of July 2025, he's serving as the mission pilot for Axiom Mission 4 to the International Space Station. 3. What kind of food do astronauts eat in space? Pre-approved, astronauts eat pre-packed, dehydrated meals. Also, non-vegetarian food is restricted.
Mint
12 hours ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
